Pooled Phase 3 data show oral peptide icotrokinra eases psoriatic arthritis pain
Among 216 participants with plaque psoriasis and self-reported psoriatic arthritis, 45.5% on icotrokinra hit 50% pain improvement at week 16 versus 16.1% on placebo.
PR
By Priya Raman · Science Reporter
Oct 17 20:00 ETSource: Journal of psoriasis and psoriatic arthritis
The wire
- 01Post-hoc pooled analysis of ICONIC-LEAD and ICONIC-ADVANCE 1 and 2 covered 216 participants (149 icotrokinra 200 mg once daily, 67 placebo) with psoriasis plus self-reported psoriatic arthritis.
- 02At week 16, 47.0% versus 10.7% achieved at least 50% improvement in patient global assessment of PsA activity, and nail psoriasis mNAPSI improved 41.6% versus 118.6% worsening on placebo.
- 03Icotrokinra, an oral IL-23 receptor-blocking peptide, is already approved for moderate-to-severe plaque psoriasis; these are post-hoc analyses with nominal P values and self-reported PsA history.
From the source
Read at pubmed.ncbi.nlm.nih.govIcotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials
Journal of psoriasis and psoriatic arthritis · 2026 Oct 18 · McInnes IB, Stein Gold L, Bissonnette R et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42898453/
